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Abstract 
 
Controlled substance abuse is a serious societal issue, particularly at the level of the actual 
addiction itself.  Opioid analgesics are painkillers that are nationally recognized as a major cause 
of death by overdose.  A number of policies and regulations have been put in place to curb 
addiction, without much success.  One potential solution is to strengthen community partnerships 
between pharmacies, clinics, physicians and other medical care providers such that 
communication is improved and red flags can be addressed more quickly. These partnerships 
have more potential than individual parties because information is gathered from multiple 
different areas of the issue. Using information from multiple aspects of the issue, a solution can 
be created to reduce addiction at multiple points. Partnerships may be able to help prevent double 
filling of prescriptions, doctor shopping, and over-prescribing reducing the amount of drugs on 
the street. By reducing the amount of drugs available on the streets, lower amounts of addiction 
will occur and hopefully prevent it.  
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I. Introduction 
Controlled substance abuse, mainly of opioid analgesics, has been a major issue 
throughout the United States and over the past 20 years, its prevalence has increased over 
threefold (Ling et al. 2). In 2013, it was estimated that 1.9 million people in the United States 
met the criteria for abuse and addiction of opioids set by the Diagnostic and Statistical Manual 
for Mental Disorders (DSM-IV) (Compton et al. 5). The abuse and misuse of these prescription 
opioids is an epidemic to which many people have lost their lives. According to the Centers for 
Disease Control (CDC), from 1999 to 2014, more than 165,000 people in the United States have 
died from prescription opioid overdose. In 2014 alone, over 14,000 people in the United States 
died from overdoses ("Prescription Opioid Overdose Data." 1). These senseless deaths could 
have easily been prevented. The number of deaths is one of the chief reasons why this problem 
needs to be addressed.  
Use of prescription opioids can lead to heroin use. Heroin is classified as an opioid. 
Opioid analgesics schedule II drugs while heroin is considered a schedule I drug. Drug schedules 
for controlled substances range from I to V as seen in Table 1. Schedule I drugs currently have 
no accepted medical use in the United States, schedule II drugs have a medical use but have an 
extremely high potential for abuse (“Drug Classifications, Schedule I, II, III, IV, V” 1). Even 
though opioid analgesics and heroin are in different schedules, they produce the same euphoric 
effect. Prescription opioid abuse can lead to heroin abuse if the person no longer has access to 
the medication. Heroin is a cheaper and more available street drug to use. In Figure 1 you can see 
a correlation of prescription opioid use and heroin use. Looking at Q2, 2011 to Q3, 2011, you 
can see how the use of the prescription opioids decreases and the use of heroin increases. In 
general, on the figure, if you see prescription opioids increasing, you see heroin decrease and 
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vice versa (Volkow 1). This figure indicates prescription opioid addicts may switch to using 
heroin if they can no longer acquire prescription opioids. 
The opioid epidemic is only growing and a solution is needed to combat addiction to 
opioid medications and stop it from killing people. One potential solution to combating opioid 
abuse is to strengthen community partnerships between pharmacies, clinics, physicians and other 
medical care providers such that communication is improved and red flags for patient abuse can 
be addressed more quickly. These partnerships have more potential than individual parties 
because knowledge from multiple aspects. Using information from multiple aspects of the issue, 
a solution can be created to reduce addiction at multiple points. One way others have tried to 
strengthen the partnership between healthcare professionals is to use a prescription drug-
monitoring program (PDMP). PDMPs have been implemented by some states but have not been 
successful in aiding the resolution to this problem due to a variety of reasons such as poor data 
collection and poor usage. I propose a nationwide PDMP needs to be developed and utilized 
rather than at the level of the states which will be discussed herein.   
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Table 1. Drug schedules with descriptions and examples for each 
schedule (“Drug Classifications, Schedule I, II, III, IV, V” 1). 	
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Figure 1. Percentage of drugs used by people to get high within 30 
days of the survey. Figure was taken from the National Institute of 
Drug Abuse (Adapted from Volkow 1). 	
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II. Regulations of Prescribing and Dispensing Opioids 
 Prescription opioid analgesics can be prescribed for pain treatment following surgery, 
chronic pain, and sometimes-even moderate pain. Unfortunately opioids are overprescribed. 
According to the CDC, in 2013, providers wrote almost a quarter of a billion prescriptions in the 
United States. This amount of prescriptions is enough for each American to have their own bottle 
of pills ("Prescription Opioids" 1). The abundance and availability of opiates outside of medical 
facilities is one of the reasons they are abused so often. Reducing the amount opioid analgesics 
are prescribed is essential to combating opioid abuse.  
 Federal regulations of prescribing and dispensing of controlled substances are mandatory 
everyone in the United States. However, each state can have its own set of regulations. The 
federal laws do tend to be less stringent than state laws and there are vast state-to-state 
differences.  
 Federal regulations must be met when writing a prescription for a controlled substance of 
any schedule. The prescription must be dated and signed on the date when it issued; it must 
include the patient’s full name and address, the doctor’s full name, address, and DEA number. A 
DEA number is an identification number assigned to healthcare workers allowing them to write 
prescriptions for controlled substances (“DEA Number” 1). In addition, the drug name, strength, 
dosage form, quantity, directions, and number of refills must appear on the prescription. Federal 
law states, there is no time limit in which a Schedule II prescription must be filled after being 
written and signed by the doctor and there is also no limit on the quantity being prescribed. The 
latter is often regulated by the states. No refills are permissible on Schedule II drugs. A 
pharmacist may take a verbal prescription from a physician in the event of an emergency and can 
dispense it provided the quantity prescribed is adequate to treat the patient during the emergency 
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situation. However, the pharmacist must receive an actual prescription within 7 days of the 
emergency period and if not, the pharmacist must notify the Drug Enforcement Administration 
(DEA) (Drug Enforcement Administration 19). 
 New York State (NYS) has its own set of regulations for prescribing and dispensing 
Schedule II controlled substances. According to NYS, every practitioner prescribing a Schedule 
II controlled substance must consult the prescription monitoring program registry in order to 
view the patient’s controlled substance history (New York State Department of Health 2). 
However, there are loopholes to this law, which is part of the reason why the PDMP is not very 
successful. Pharmacists have access to this registry as well if they feel the need to check a 
patient’s history. Compared to federal regulations, NYS requires more information on controlled 
substance prescriptions such as the patient’s sex, age, the maximum daily dosage, as well as the 
quantity in numerical and written form. As stated above, some states put a limit on the quantity 
of pills per prescription and for NYS a 30-day supply for controlled substance prescriptions is 
the limit. A physician may write for a 90-day supply, however, the prescription must be 
documented with specific codes representing treatments for certain diseases. Under NYS law, a 
patient may not receive multiple prescriptions for controlled substances within 30 days of the 
first prescription until a patient has 7 days left of the original prescription. In contrast, Iowa, 
Utah, and New Jersey allow multiple prescriptions for schedule II controlled substances to be 
dispensed ("Prescription Drugs" 1). As stated above, federal guidelines allow verbal 
prescriptions in emergencies; but NYS limits the verbal prescription to a 5-day supply. In NYS, 
the pharmacist must still receive a written or electronic prescription within 72 hours of the verbal 
prescription (New York State Department of Health 3).  When dispensing and selling a 
prescription, only some states require identification of the patient picking up the medication. For 
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the states that do require identification such as Maine, Oregon, and New York, the type of 
identification is different for each. Maine requires proper photo identification, Oregon requires 
“proper” identification, and New York requires “appropriate” identification ("Prescription 
Drugs" 1).  
 As you can see, NYS along with others has attempted to enact stricter regulations on 
opioids than the federal government in an effort to curb opioid addiction. However, each state 
can differ in regulations, indicating the federal regulations are the only stable and consistent 
regulations state to state.  
III. Addiction 
 Addiction is defined as when someone who is dependent upon something, such as 
prescription painkillers, and they need it to function physically and mentally. The compulsion to 
use drugs involves the failure to resist cravings. People can become addicted to prescription 
opioids easily and not even know it until they try to stop taking the pills. One way to view 
addiction is a brain disease in which the brain becomes chemically dependent on the substance. It 
has been suggested when a brain is constantly bombarded it forms unusual adaptations and 
becomes dependent on that particular substance (Tommasello 3). Addiction to prescription 
painkillers not only affects the brain and nervous system, but also induces respiratory 
suppression, drug-drug interactions, and other risky behaviors including the use of other drugs 
and alcohol (Ling et al. 301). 
 Opioids have two clinically significant properties: physical dependence and tolerance. 
Tolerance refers to prolong exposure to opioids that results in the requirement to raise the dose of 
a drug to achieve a constant analgesic effect. Physical dependence refers to the physiological 
response to abstinence or opioid reversal in a patient who has been taking opioids continuously 
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(Vallejo et al. 344). A response to an opioid depends on the presence and activity of a specific 
membrane receptor. Opioid receptors and related signaling pathways are being studied to gain a 
better understanding of the action of opioids on the body. 
 The brain, spinal cord, and peripheral sensory and autonomic nerves have guanine 
protein-coupled receptors (GPCRs) where opioids bind. The delta receptor, the mu receptor, and 
the kappa receptor are the three main subtypes of opioid receptors, but there may be more 
significant subtypes in existence. The mu opioid receptor has been identified as the central 
subtype responsible for supra-spinal and spinal pain relief. Opioids produce analgesic effects by 
stimulating pain perception. Endorphins, enkephalins, and dynorphins are endogenous opioid 
peptides found in the brain. These opioids inhibit pain results by hindering calcium entry in the 
presynaptic membrane, inhibiting neurotransmitter release, hyperpolarizing presynaptic cells by 
raising potassium outflow, preventing nociceptive afferent information from distributing to 
neighboring neurons, and monitoring nociceptive information at the limbic system. By doing so, 
the neurons are inhibited from firing action potentials to transmit pain signals to the brain 
(Vallejo et al. 344-345).   
Different interactions can occur between a receptor and opioids therefore opioid 
painkillers can be sorted into four different categories based on the nature of the receptor-opioid 
interaction: agonists, antagonists, agonist-antagonist, and partial agonists. An agonist will bind to 
the receptor and stimulate physiological activity with no limit to their analgesic effects. 
Antagonists can interfere with the actions of agonists if both are interacting with the same 
receptor. Agonists and antagonists have different effects depending on what receptor it binds to. 
Receptor type (mu, kappa, delta) can influence the type of effect an agonist or antagonist will 
have. A partial agonist has a low maximal response of opioids indicating there is a limit to the 
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analgesic effects (Vallejo et al. 345-346). Table 2 below shows the classifications of opioids into 
the four categories discussed (Vallejo et al. 347) 
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Table 2. Classification of opioids by mechanism of action in the body (adapted from 
Vallejo et al. 347) 
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One of the highly addictive effects of opioids is opioid-induced euphoria. The 
GABAergic neurons of the nucleus accumbens (NAcc) regulate opioid-induced euphoria within 
the central nervous system. Dopaminergic (DA) neurons within the ventral tegmental area 
(VTA) send out projections and integrations to the NAcc included in the prefrontal cortex, and 
amygdala when excitation occurs from opioids. These pathways innervate the 
mesolimbic/mesocortical pathways, which are dopaminergic pathways. Innervation of these 
pathways allows for the release of dopamine, resulting in the euphoric effect. 6-keto opioids 
(hydrocodone, oxycodone, and hydromorphone) are prominent for producing euphoric effects 
and have a higher likelihood, when compared to other opioids, of being abused (Vallejo et al. 
344). The euphoric effects can be the reason individuals crave more and more of these drugs and 
eventually leads to addiction. Thus the biology behind opioid addiction is complicated and steps 
must be taken to improve communication between healthcare professionals and the community 
to help prevent these drugs from being used.  
Individuals can become addicted to opioids through drug misuse or abuse. A patient may 
not know the dangers of what can happen when they take more medication than is prescribed and 
once they begin, they cannot stop. Drug abuse occurs when a patient is knowingly taking more 
than prescribed. In addition, genetic risk factors can facilitate drug addiction. For example, if a 
person’s parent is an addict, that person is more likely to become an addict. Addiction following 
drug experimentation with heroin is very high, resulting in about 25 to 40% becoming addicts 
after the first exposure (Tommasello 3). 
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IV. Treatment  
 Treatment options for prescription opioid addicts include, but are not limited to, 
medications, rehabilitation, and outpatient and inpatient clinics. Medications such as methadone, 
buprenorphine, and buprenorphine/naloxone (Suboxone) are used in the treatment of opioid 
addiction. These are controlled substances used as ‘substitution’ or ‘maintenance’ medications in 
order to deter patients from using illegal opioids in hopes of reducing addiction-related behaviors 
(Ling et al. 304). It is important to prescribe just the right dose of these substitute medications 
because if the dosing is incorrect, the maintenance is not going to work and can potentially make 
the abuse worse. For instance, if the dose is too strong, the patient may become addicted to the 
maintenance medication itself. Methadone is the maintenance medication that has been used in 
the past to treat addiction, however, methadone is an agonist opioid. This means the methadone 
is still giving the euphoric high; therefore, it can have a high potential for abuse. Since 
methadone has a high potential for abuse, doctors are now prescribing suboxone (Turner et al. 
24). Suboxone, a mixture of buprenorphine and naloxone, is an oral film medication that 
dissolves on the tongue. Referring to Figure 2, it can be seen the active drugs in suboxone consist 
of an antagonist and partial agonist. This film is being prescribed more due to the inclusion of 
naloxone hydrochloride, which acts as an opioid antagonist, meaning it can reverse the effects of 
opioids in the body (Turner et al. 24). Figure 2 below shows the increasing usage of suboxone 
over ten years starting around 125,000 treatments in 2003 to over 500,000 treatments in 2011 
(Turner et al. 26).  
 In addition to maintenance medications being used for treatment of prescription opioid 
abuse, a medication called Narcan, naloxone hydrochloride, is used in emergency overdose 
situations. Narcan is used to treat an overdose but not maintenance. As stated above, naloxone 
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hydrochloride acts as an opioid antagonist meaning it reverses the effects of opioids. Narcan is 
used as an attempt to reverse the effects of the opioids when a person has overdosed. Looking at 
treatment visits alone, it can be seen there is an increasing number of addicts and it is only 
continuing to grow.  
A consequence of addiction is that through constant exposure to a chemical, the brain 
becomes dependent upon it. Withdrawal symptoms can make it hard to treat addiction to opiates. 
In the early stages, symptoms include, but are not limited to, agitation, anxiety, muscle aches, 
insomnia, and sweating. Later stages can include abdominal cramping, diarrhea, dilated pupils, 
goosebumps, nausea, and vomiting (“Opiate and Opioid Withdrawal” 1). These symptoms can 
start within 12 hours of the last use of short-acting opiates and 30 hours for long-acting opiates 
(“Opiate Withdrawal Timelines, Symptoms and Treatment” 1). These symptoms can be 
incredibly difficult for addicts to handle and often require medical treatment. Addicts may feel 
they have no other choice than to continue using because they may not know about, or want to 
use, the resources offered to help combat their symptoms (“Opiate Withdrawal Timelines, 
Symptoms and Treatment” 1). 
There are a variety of resources for people to reach out for help. These may include 
doctors, pharmacists, nurses, clinics, and friends. Not only is there help to treat addiction and 
withdrawal, there is help on an emotional level as well. Support groups exist for people battling 
addiction in which people can go and talk with other recovering addicts for help (“Opiate and 
Opioid Withdrawal” 1). If there were more widespread knowledge regarding treatment options, 
more addicts may reach out for help. By increasing the number of community partnerships that 
exist between rehabilitation and treatment clinics, other healthcare professionals, and community 
leaders an increase of patient awareness and access to the availability of treatment may occur.  
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Figure 2. Trends in ambulatory treatment visits using buprenorphine products for 
opioid dependency, 1997-2013. (Adapted from Turner et al. 26). 	
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V. How people acquire controlled substances 
 The availability of opioid analgesics is contributing to opioid abuse. Drug dealers are the 
main source of access to opioids, from which 70 to 80% of users acquire their opioids. Dealers 
acquire prescription analgesics using an array of drug diversion tactics (Rigg et al. 144), which 
can be defined as illegally feeding controlled pharmaceuticals from legal sources into an illicit 
marketplace (Inciardi et al. 171). Studies have been conducted using qualitative interviews in 
order to gain more empirical data. One study that was conducted in several South Florida areas 
used a sample of 50 people in order to learn more about different drug diversion types. This 
study discovered six predominant mechanisms of drug diversion; including pain clinic shopping, 
the buying scripts, sponsorship, and using a ‘connect’ (Rigg et al. 148). However, all of these 
ultimately lead back to the pharmacy. Another study was conducted in Miami, Florida in which a 
total of 17 focus groups were studied from a variety of different drug-using populations. This 
study concluded that while certain drug diversion tactics are used most often, there are other 
street based markets also being used to purchase illicit drugs (Inciardi et al. 171). In order to 
produce a solution, it is important to understand how the substances are reaching the streets from 
all aspects, which can better prevent dealers getting their hands on the drugs.  
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Figure 3. Results of investigation into the primary sources of prescription drug 
diversion (Adapted from Inciardi et al. 173) 
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Figure 3 shows the general results of the study focused in Miami but the research focuses 
more on the drug diversion tactics of insurance fraud and theft of drugs. Many people do not 
think about Medicaid and Medicare fraud as being a well used method. Several study 
participants in Miami indicated one of the major ways to obtain pills was through a “pill broker”, 
or someone who uses Medicaid fraud to obtain a supply of pills. The dealer sends an older man 
into a physician’s office to complain of pain, the doctor gets reimbursement from Medicaid for 
every patient he sees. As a result, if the doctor helps out the dealer, the dealer will send more 
patients his way. The dealer pays the patients for the pills and then sells them to users (Inciardi et 
al. 174). Unethical doctors, who participate in this, add to the issue by prescribing more opioids 
aiding in the distribution. Focusing on just preventing doctor shopping does not help solve the 
issue of crooked physicians, which is why we need to understand other forms of drug diversion. 
We must propose a solution that covers all kinds of sources. Partnerships between law 
enforcement and health care professionals could help prevent the widespread availability of 
opioid analgesics. In addition, a nationwide PDMP could prevent doctor shopping by tracking all 
opioid prescriptions (Shepherd 110).  
Pain clinic shopping was found to be the most widely used tactic of obtaining 
prescription opioids. In order to obtain multiple prescriptions for the opioids, dealers would visit 
several pain management clinics complaining of chronic pain and show a doctored MRI in order 
to get the medications. One of the people interviewed stated, “if you go in and say your pain is a 
10 they will give you 240 Oxy’s or if you say 5, 6, or 7 you will get 160 Oxy’s.” The doctors 
don’t do any tests or even examine the patient, they just prescribe (Rigg et al. 149). This is a vital 
moment where pharmacists could help stop the constant flow of pills from clinics. People who 
get multiple prescriptions from pain clinics need to use multiple pharmacies in order to avoid 
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detection. If a PDMP reported all controlled substance prescriptions and was actually utilized by 
all pharmacies, they would be able to catch these people and refuse to fill these various pain 
clinic scripts. This ultimately would reduce the omnipresence of opioids and diminish the 
amount of addiction (Shepherd 87).  
 Another way dealers obtain opioids is buying prescriptions from people in their 
communities willing to sell. One tactic used by drug dealers is to seek out individuals who are 
desperate enough to sell their prescriptions for quick cash (Rigg et al. 152). Another tactic used 
by drug dealers is sponsorship, which is when dealers pay for someone else’s trip to a pain clinic 
in return for a portion of the medication prescribed (Rigg et al. 150). This method allowed 
dealers to increase their stock of medication because they could sponsor various people to go to 
different pain clinics but if they went themselves, the prolonged waiting times would limit the 
amount of visits they could make. A ‘connect’ could often be used by dealers to obtain 
prescription opioids. The word ‘connect’ is used to describe an individual who has steady access 
to prescription drugs by working in a healthcare setting (Rigg et al. 152). Using this technique, 
the ‘connect’ would provide the dealer with prescription pads or prescription medications stolen 
from the facility they were employed with.  
 Dealers commonly use these various methods in order to obtain prescription medications, 
however, they all have one thing in common: the medication is coming out of the pharmacy. This 
indications solutions to the opioid crisis need to include pharmacists because they are dispensing 
the medications. Findings from this study have created support in the crafting of Florida’s 
proposed prescription drug monitoring program (PDMP) (Rigg et al. 155). This data should not 
only support a PDMP for Florida, but should support one for the entire United States as one 
possible solution to this epidemic.      
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VI. Doctors Views of Opioid Abuse 
 Doctors play an essential role in opioid addiction because they are the ones prescribing 
opioids. Doctors need to be the first round of defense in preventing and combating addiction to 
opioids. The public tends not to know much about physician’s attitudes and policies towards 
prescription opioid abuse or they have incorrect assumptions. In order to understand physician’s 
beliefs on opioid abuse, two studies were conducted in which surveys were sent out to 
physicians, which asked a variety of questions surrounding opioid abuse and addiction 
(Kennedy-Hendricks et al.), (Hagemeier et al.). 
 The first study was conducted in 2014 and consisted of 1010 participating primary care 
physicians answering various questions regarding opioids on a 5-point Likert scale (strongly 
disagree to strongly agree). In addition to asking questions about opioids, the physicians were 
also asked to answer questions regarding their own medical careers, such as medical school 
information, prescribing patterns, practice setting, and state that they practiced in. It was found 
that 72 % of respondents felt prescription opioid abuse was an extremely serious problem facing 
the United States. If doctors do not see this as a major issue, they are not going to put the effort 
in to help make it stop. Using Table 3, we can understand some of doctor’s beliefs regarding the 
major causes of opioid addiction. Out of the entire sample, 85% of physicians agreed it is too 
easy for people to obtain multiple prescriptions for opioids from multiple different doctors. This 
observation supports the theory of people using “doctor shopping” as a main source for these 
drugs. Table 2 also shows 90 % of the doctors surveyed agreed some people do not really 
understand how easy it is to become addicted to prescription painkillers (Kennedy-Hendricks et 
al. 65). This doctor perception can show how uneducated people really are when it comes to 
taking these medications and how dangerous it can be to take these painkillers.  
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Table 3. Shows tabulated data of physicians responses to different causes of opioid 
addiction (Adapted from Kennedy-Hendricks et al. 65). 
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The survey asks doctors about how best to support interventions into this epidemic. The 
results are tabulated in Table 4. The most popular ideas from physicians were having 
identification verification requirements at pharmacy pick up (96%), having prescription drug 
monitoring programs in all states (92%), requiring medical schools as well as residency 
programs provide adequate training on addiction detection and treatment (91%) and lastly 
adequate training in medical school and residency on how to treat chronic pain correctly (90%) 
(Kennedy-Hendricks et al. 67). Physicians do understand the problems surrounding opioid abuse 
as well as their role in solving the issue. If we can get doctors on board for increasing community 
partnerships and utilization of a nationwide PDMP solving the opioid epidemic is more likely to 
occur.  
 The second study from 2012 surveyed prescribers as well as pharmacists. This study 
focused more on recognizing addiction and successful treatment. When asked if individuals 
receiving opioid painkillers could be recognized as abusers of the drug, only 17% of prescribers 
agreed they could recognize abusers whereas 41% of pharmacists agreed they could recognize 
abusers. In addition, when asked if individuals receiving these medications had a legitimate 
medical necessity for painkillers, prescribers responded say 85% of patients did whereas 
pharmacists stated only 64% of patients had a medical necessity for the opioids. These numbers 
indicate a colossal disconnect in communication between healthcare professionals. These types 
of community partnerships are essential in creating a solution that will actually work to curb 
opioid abuse and addiction. Respondents to this survey, both pharmacists and prescribers, 
strongly agreed (80-90%) an increase in communication of the prescriber-pharmacist-patient 
triad would be beneficial. One reason why pharmacists perceive more patients as abusers is they 
do not have as close of a relationship with the patients because they just come to get their 
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medication and leave. Because of that, pharmacists may have a more objective view when it 
comes to identifying addicts (Hagemeier et al. 787). Results of this study also support the use of 
a prescription drug-monitoring program to close the communication gap between healthcare 
professionals. However, the current PDMPs do not currently collect and communicate certain 
data that may be useful in the estimation of abuse. Revamping the PDMPs in all states with a 
higher focus on the partnerships between health care professionals would help prevent abusers 
from receiving prescription painkillers.  
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Table 4. Tabulated data showing physician’s support on proposed solutions to combat 
prescription opioid abuse (Adapted from Kennedy-Hendricks et al. 67).   
	Uttaro	27	
In addition to these two studies, Anna Lembke, M.D., published a paper in the New 
England Journal of Medicine in October of 2012 highlighting why she believes there are so 
many opioids being prescribed, especially to known abusers. Around 60% of opioids that are 
abused come from doctor’s prescriptions and the reasons doctors prescribe so many are not well 
known to the public. Dr. Lembke states, in many instances, prescribers are aware of the patient 
abusing opioids but still prescribe anyway. Changes in the medical society’s attitude of pain 
treatment, societal views towards suffering, and monetary deterrents for treating addiction are 
some explanations attributed to this problem (Lembke 1580). A physician is supposed to be 
someone who patients can trust to help get better, not feed an addiction.  
Over the past 100 years, views of how to treat pain have changed drastically. It used to be 
argued pain was an important part of the healing process and many doctors spoke out against the 
use of pain remedies (Lembke 1580). However, in society today, health care providers have been 
urged to trust a patient’s subjective experience and expression of pain as precedence over other 
considerations during treatment. Physicians are beginning to feel pressured into prescribing due 
to patient satisfaction surveys, which can affect a physician’s reimbursement and job security. If 
a doctor says “no” to prescribing opioids they are likely to receive bad feedback and not receive 
as many patients (Lembke 1580). If a doctor does not have enough patients, there is no way for 
he or she to keep a practice open. This pressure can cause doctors to just write the prescription 
whether or not they believe the patient is abusing drugs. In addition to the pressure to prescribe 
from patient satisfaction, doctors are also feeling the pressure to prescribe due to the belief 
untreated pain can cause psychic scars which leads to a form of post-traumatic stress disorder 
(PTSD). Doctors who decide not to prescribe opioids for pain may be seen as withholding care 
and causing additional trauma and no doctor wants that guilt on their shoulders. Patients are 
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keenly aware of these pressures and use them to their advantage to gain more and more opioids. 
If a doctor refuses to prescribe, a patient may sue for withholding medical care and inflicting 
more harm (Lembke 1580). For physicians, prescribing opioids seems to be a double-edged 
sword. They either prescribe and feed someone’s addiction or refuse to prescribe and have 
adverse affects on their professional careers.  
 Dr. Lembke also points out the sad but true fact that treating pain pays, while treating for 
addiction does not. Treating addiction takes extensive education and effective counseling which 
both take time. Physicians are often evaluated on how many patients they are seeing and not the 
time spent with patients (Lembke 1581). Prescribers will not take the time to effectively educate 
and counsel a patient about addiction until they are sufficiently compensated for the time it takes. 
It is much faster to diagnose pain and write a prescription than it is to diagnose and treat 
addiction (Lembke 1581). A physician should not have to worry about how many patients they 
seeing; they should be worrying about whether or not they are effectively treating their patients. 
Doctors should not be evaluated on quantity; they should be evaluated on quality.  
 Some short-term changes Dr. Lembke offers are mandating all physicians to complete 
continuing education courses on addiction and not just pain treatment and having access to 
PDMP’s and by law having to access the database before writing the prescriptions (Lembke 
1581). Furthermore, if the government and health care professionals worked together to come up 
with better laws and mandates regarding prescribing, a solution may arise. To add to the 
suggested mandate of sending doctors to an addiction education course, doctors should no longer 
be evaluated or paid for prescribing opioids; they should be evaluated on treating addiction and 
paid for that. In doing so, one of the major pressures of prescribing will be eliminated hopefully 
encouraging prescribers to diagnose addiction and treat it.  
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 Doctors may be the most influential people to help prevent and stop opioid addiction 
because they are at the start of the cycle. Solutions to the opioid epidemic should start with 
doctors and expand outward through partnerships with other healthcare professionals as well as 
the community. In creating these partnerships, communication will increase throughout the 
community and red flags of addiction can be caught sooner and taken care of.   
VII. Pharmacists Views of Opioid Abuse 
 Pharmacists play a critical role in the fight along with physicians being on the front line 
to battle the opioid crisis. Pharmacists are the second healthcare professionals patients see when 
receiving the opioid analgesics. Often more times than not, patients see pharmacists more 
frequently than physicians. Pharmacists are the second line of defense in identifying addiction in 
patients, which indicates they should play a large role in finding a solution to the opioid 
epidemic.  
 A study done in 2012 compared prescriber and pharmacist’s opinions on prescription 
opioid abuse. This study gave an insight to the differences between pharmacist interactions and 
prescriber interactions with patients. Participants in this study were asked what percentage of 
prescriptions written for opioid analgesics were prescribed to abusers, pharmacists responded 
41% and prescribers only 17%. This indicates pharmacist interactions with patients are different 
than with the prescriber (Hagemeier et al. 785). If pharmacists are responding saying almost half 
of the prescribed opioids are for abusers, they are clearly experiencing differences in patients a 
physician may not see. This can indicate abusers are putting on a show for prescribers in order to 
get the prescription, but once they have the prescription they do not care enough to put on a show 
for the pharmacist. Furthermore, when asked if individuals receiving opioid painkillers had a 
medical necessity for the drug, pharmacists responded saying 64% were legitimate reasons 
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whereas prescribers responded with 85% were legitimate reasons (Hagemeier et al. 785). This 
again may indicate there are differences in observed behavior as well as interactions with 
patients between pharmacists and doctors.  
 The study from 2012 is indicative of a sizeable communication gap between pharmacists 
and prescribers, which can be detrimental to producing a successful solution to opioid abuse. 
Closing this gap should be the first step in solving the issue at hand. Pharmacists have been 
attempting to communicate more with providers by calling on questionable prescriptions or 
calling to verify the legitimate medical reason, however, it has been challenging due to a few 
reasons. Two core challenges to this are the time it would take to improve the communication as 
well as physicians being worried whether or not pharmacists are qualified enough to intervene in 
medical decisions. Providers have stated they are uncomfortable when a pharmacist is 
questioning their medical decisions and treatments due to concerns of pharmacists not having the 
capability to accurately question prescriptions (Hoppe et al. 1997). However, many of these 
concerns are unwarranted because pharmacists are in school for 6 to 8 years with numerous 
instances of hands-on experience dealing with patient care decisions (Hoppe et al. 1997). 
Reassuring providers of the extent of a pharmacist’s education may help alleviate those concerns. 
Time is limited and workload is high so more communication between a provider and a 
pharmacist is a burden to many. Time is the reason many providers do not check PDMPs if there 
is one available (Hoppe et al. 1997). However, even though time is limited, it should not be a 
burden for a provider to verify prescriptions with a pharmacist or provide a diagnosis or rationale 
for prescriptions that are deemed unusual or unsafe. Improving the communication would benefit 
and improve patient safety, which should be the ultimate concern of both doctors and 
pharmacists.  
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 Utilizing both pharmacists and physicians needs to be the focus of a solution to the opioid 
crisis. Both of these health care areas have direct contact with the patients in different settings in 
order to make inferences regarding the patient as an addict or not. In order to make more 
accurate inferences, enhanced communication is vital. In addition, using the knowledge of both 
physicians and pharmacists, gives better odds at identifying and treating addiction.  
VIII. Strides Being Made to Fix the Issue 
 The opioid crisis has been a critical societal issue for many years and there have been 
various attempts to help curb this disaster, however, these efforts have not been successful. Steps 
have been made at both the federal and state level.  
 For instance, Former President Obama had visited West Virginia in October of 2015 to 
hear local concerns regarding the opioid abuse epidemic. He was stunned when he heard the 
statistics presented by the CDC, which indicated more people are dying from drug overdoses 
than from car accidents. As a result of this meeting, the White House ordered federal agencies to 
ensure employees who are involved in the prescribing of controlled substances complete training 
related to the appropriate use of the drugs within 18 months. The training had to include the best 
practices for the proper and effective prescribing of pain medications, the connection of 
substance abuse with controlled substances, safe discarding of controlled substances, and the 
prospective misuse of controlled substances (Traynor 1). This is a brilliant idea because a big 
part of this epidemic is people are just simply uneducated when it comes to these types of drugs.  
 New York State (NYS) enacted a law on March 27, 2016 mandating the use of electronic 
prescribing by practitioners. Electronic prescribing means a practitioner sends an e-prescription 
to a pharmacy to be dispensed to a patient instead of the patient bringing a written prescription to 
the pharmacy. Controlled substance e-prescriptions require additional security features in order 
	Uttaro	32	
to deter forged prescriptions. This law was enacted not only to help reduce the amount of errors 
due to poor handwriting on written prescriptions but also to reduce theft and forgery of written 
controlled substance prescriptions (Bureau of Narcotic Enforcement 1). This is a small step in 
reducing the amount of fake prescriptions brought in to pharmacies for prescription opioids. 
However, this is only mandatory in NYS, federal agencies encourage the use of electronic 
prescribing but do not require it. If this was made a nationwide law, it would help deter the use 
of fraudulent prescriptions and ultimately prevent dealers from getting their hands on so many of 
these pills.  
 One way states have tried to combat opioid abuse is by implementing PDMPs. Most 
states had developed some sort of PDMP beginning in the 1990s and 2000s. A PDMP has a few 
goals: supporting legitimate medical use of controlled substances; preventing drug diversion and 
abuse; allowing the identification of prescription drug addicts to allow for intervention and 
treatment; and education about drug abuse and addiction. However, many of these States’ 
PDMPs have been unsuccessful due to poor data collection, deficient utilization of data, 
inadequate data sharing between states, and not allowing law enforcement access to the PDMP 
(Shepherd 87).  
 Poor data collection can cause a PDMP to be useless because if the data that is needed is 
not in the PDMP, healthcare professionals cannot benefit from its use. Many of the state PDMPs 
in use, do not require certain vital information that is needed to make it useful. For example, 
most state PDMPs in use do not require the method of payment for controlled substance 
prescriptions. When a customer pays cash for a prescription, the customer evades insurance 
companies monitoring the number of prescriptions. If a customer uses insurance, the insurance 
companies can detect potential abuse by the frequency of claims and inappropriate prescribing 
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(Shepherd 87). In addition, most PDMPs do not require the identification of the person picking 
up the prescription. Drug diversion could be detected if someone other than the individual the 
drug is prescribed to is continually picking up the dispensed medication (Shepherd 94). PDMPs 
currently do not gather any prescriber deaths or punitive actions against a prescriber. Because of 
this, pharmacies may dispense controlled substances from a prescriber that is banned from 
prescribing the medications by the DEA. Ultimately the pharmacy will receive this information 
but in the meantime, pharmacies are dispensing illegal prescriptions to patients. Many states 
argue collecting all this additional information increases workload and lengthens the process of 
prescribing, dispensing, and selling controlled substances, however, others agree the added 
workload is worth the work to help prevent addiction (Shepherd 106). 
 Many states do not legally require the utilization of the PDMP by prescribers and 
pharmacists. Most prescribers and pharmacists find it a hassle to have to consult the database for 
each prescription. If healthcare professionals are not being legally required to utilize the PDMP, 
what good is it? In addition, it can take up to a month for information to be available through a 
PDMP (Hildebran et al. 6) . This is an issue because if someone is actually looking for current 
data, it is not there (Shepherd 106).  
 State PDMPs do not have adequate information sharing between states. Some states do 
not have PDMPs leaving a huge gap in communication and allows drug addicts to take 
advantage. Drug addicts may procure opioid prescriptions from multiple states particularly 
neighboring states in order to evade detection (Hildebran et al. 6). Also, most state PDMPs are 
different which makes data sharing extremely difficult and time consuming (Shepherd 107). If 
there is lack of communication between states, this allows drug addicts to fill prescriptions in 
multiple states evading detection.  
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 Lastly, most state PDMPs do not allow law enforcement to access the information. States 
exclude law enforcement because of the fear law enforcement will use it improperly (Shepherd 
108). In addition, much of the information in a PDMP is personal healthcare information 
regarding patients, which is legally protected, meaning law enforcement agencies need warrants 
to access healthcare records. Prescribers may fear law enforcement agencies allowed access to 
PDMPs may invade an individuals privacy (Shepherd 108).  
IX. Proposed Nationwide PDMP 
 After analyzing all the data, a nationwide PDMP should be enacted in order to fight 
controlled substance abuse. A nationwide PDMP would make it so each state is utilizing the 
same program resulting in no data sharing barriers. Some of the vital information including the 
patient’s diagnosis, identification of individual picking up the medication, patient’s method of 
payment, prescriber information, and pharmacy information should be included in a country 
wide PDMP. A PDMP would increase the community partnerships between healthcare 
professionals in order to detect rogue prescribers, rogue pharmacists, doctor shopping, pharmacy 
shopping, and drug diversion.  
 If a PDMP was federally mandated to be used by prescribers and pharmacists for each 
controlled substance the number of abusers and addicts would go down. This would allow red 
flags to be taken care of before the medications are dispensed and sold. In addition, there would 
be no communication gaps in which abusers could take advantage of to gain access to the 
medications.  
 Finally, if healthcare professionals were allowed to use the database to notify law 
enforcement agencies of potential crime, it would allow law enforcement to crackdown on illegal 
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activity (Shepherd 108). It would increase the partnership between law enforcement and 
healthcare professionals and allow more teamwork in combating the epidemic.  
X. Conclusion 
 The current opioid analgesic abuse and addiction in the United States is an epidemic, 
which has had attempts to control, needs a nationwide solution in order to be successful. A 
variety of community partnerships need to be built and maintained between healthcare 
professionals, healthcare facilities, community leaders, emergency services, and law 
enforcement. These community partnerships would increase communication between parties in 
order to pool knowledge to prevent and control abuse and addiction.  
A nationwide PDMP is a great start to building these partnerships by having a sole source of 
information surrounding individuals receiving prescription opioids. This will open 
communication channels between physicians and pharmacists as well as law enforcement to 
ultimately detect potential abuse.  
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